Women's Care Florida / Women's Cancer Associates
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Whitaker, Amy
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
NCT05788484: A Study of CDX-585 in Patients With Advanced Malignancies

Active, not recruiting
1
130
US
CDX-585
Celldex Therapeutics
Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
05/25
05/25
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Active, not recruiting
1
198
Europe, US
NG-350A plus Pembrolizumab, KEYTRUDA®
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
FIT-001, NCT06026410: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Recruiting
1
270
US
KO-2806, Cabozantinib, Cabometyx, Adagrasib, Krazati
Kura Oncology, Inc., Mirati Therapeutics Inc.
Solid Tumors with HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer)
01/27
04/27
Indermaur, Megan
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer

Checkmark Presentation of OVATION 2 data in advanced ovarian cancer
Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer
Active, not recruiting
1/2
130
Canada, US
IMNN-001, Carboplatin, Paclitaxel
Imunon
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
07/24
11/25

Download Options